SIGA Technologies Inc. - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the development and sale of TPOXX® (tecovirimat), an antiviral drug for the treatment of smallpox. The company primarily sells oral and intravenous (IV) formulations to the U.S. Government (via BARDA and DoD contracts) and international governments.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $21.8 million | $5.9 million | $47.2 million | $14.2 million |
| Net Income/(Loss) | $1.8 million | ($2.9) million | $12.1 million | ($3.8) million |
| Operating Income/(Loss) | $1.1 million | ($4.6) million | $12.4 million | ($6.7) million |
| Cash and Equivalents | $106.9 million (as of June 30, 2024) | |||
| Deferred Revenue | $13.7 million (as of June 30, 2024) | |||
| Inventory | $55.7 million (as of June 30, 2024) | |||
| Effective Tax Rate (YTD) | 22.4% |
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 271% year-over-year for the quarter and 233% year-over-year for the six months. This was driven by $17.6 million in IV TPOXX® sales to the U.S. Government and $3.0 million in international sales in Q2 2024, compared to minimal product sales in the prior year periods.
- Profitability Turnaround: The company reported a net income of $1.8 million in Q2 2024, reversing a net loss of $2.9 million in Q2 2023. YTD net income was $12.1 million versus a loss of $3.8 million in the prior year.
- Cost Structure: Cost of sales increased significantly to $12.3 million in Q2 2024 (from $1.0 million in Q2 2023) due to the delivery of IV TPOXX® and international oral TPOXX®. SG&A expenses rose to $5.5 million due to higher promotion fees and executive compensation.
- Dividend Payment: The company paid a special cash dividend of approximately $42.7 million in the first half of 2024, compared to $32.1 million in the same period in 2023.
Guidance, Outlook, and Risks
- Contract Options: Subsequent to the quarter end (July 18, 2024), BARDA exercised an option for $112.5 million of oral TPOXX®, increasing cumulative exercised options to $519.6 million. Unexercised options remain at $31.2 million.
- Regulatory Pipeline: SIGA is targeting a Supplemental NDA filing for a smallpox post-exposure prophylaxis (PEP) indication within the next 12 months. A potential submission for an mpox indication could occur as early as 2025, contingent on clinical trial results.
- Liquidity: Management believes current cash resources ($106.9 million) are sufficient for at least the next 12 months. There are no long-term debt obligations listed on the balance sheet.
- Risks: Key risks include the U.S. Government's discretion to exercise or terminate contract options, supply chain disruptions, and the uncertainty of regulatory approvals for new indications (mpox/PEP).
Investor Verification Checklist
- Verify the status and timing of the Supplemental NDA filing for smallpox PEP and potential mpox indications.
- Monitor the exercise of remaining unexercised options under the 19C BARDA Contract ($31.2 million remaining).
- Review the gross margin profile of IV TPOXX® sales, which management estimates to be less than 40% under current contract terms.
- Assess the impact of the amended International Promotion Agreement (effective June 1, 2024) on future international revenue recognition and Meridian's fee structure.
- Confirm the sustainability of cash flows given the significant dividend payout ($42.7 million YTD) and ongoing inventory build-up ($55.7 million).